🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Placebo (Vehicle) for investigational DFL24498, Isocyclosporin A, DEXAMETHASONE

    Dompe' Farmaceutici S.p.A.

    Atopic Keratoconjunctivitis

    phase 3 small molecule active

    1 trial

  2. Placebo Spiromax

    Teva Pharma GmbH

    Asthma

    phase 3 small molecule terminated

    1 trial

  3. Placebo de fasturtec, Fasturtec 1.5 mg/ml powder and solvent for concentrate for solution for infusion.

    Pari Pharma GmbH

    Patients hospitalised in intensive care, diagnosed with sepsis less than 48 hours ago, uric acid level ≥200µmol/L, adults, negative G6PD deficiency

    phase 3 small molecule active

    1 trial

  4. Placebo de formule développée spécifiquement pour la recherche par la PUI (cf IMPD-Q), CLOBETASOL PROPIONATE

    Pari Pharma GmbH

    Adult patients with symptomatic and inflammatory Hand osteoarthritis HOA.

    phase 3 small molecule active

    1 trial

  5. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Adults Non Diabete Remission (NDR) Type 2 Diabete (T2D) patients 1 to 5 years after bariatric surgery

    phase 3 small molecule active

    1 trial

  6. Placebo double encapsulated oral transplant of fecal microbiota, Double encapsulated oral transplant of fecal microbiota

    Pari Pharma GmbH

    Patients colonized with MDR-GNB

    phase 3 small molecule active

    1 trial

  7. Placebo for ASPAVELI 1 080 mg solution for infusion, ASPAVELI 1 080 mg solution for infusion

    Lacuna Pharma Pty Ltd

    complement 3 glomerulopathy (C3G)/immune complex membranoproliferative glomerulonephritis (IC-MPGN)

    phase 3 small molecule active

    1 trial

  8. Placebo for Opdivo, Rubraca 200 mg film-coated tablets, Rubraca 250 mg film-coated tablets, Rubraca 300 mg film-coated tablets, OPDIVO 10 mg/mL concentrate for solution for infusion., Placebo for Rubraca

    pharmaand GmbH

    Ovarian epithelial cancer, Malignant peritoneal neoplasm, advanced (FIGO stage III-IV), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer (who responded to front-line platinum-based chemotherapy), Fallopian tube cancer

    phase 3 small molecule active

    1 trial

  9. Placebo for cemdisiran is 0.9% saline and will be supplied by the sponsor., Pozelimab, Placebo for pozelimab will be provided in an aqueous buffered solution and supplied by the sponsor., Cemdisiran

    Lacuna Pharma Pty Ltd

    Geographic Atrophy Secondary to Age-Related Macular Degeneration

    phase 3 small molecule active

    1 trial

  10. Placebo for pembrolizumab, KEYTRUDA 25 mg/mL concentrate for solution for infusion, CAPECITABINE , FLUOROURACIL , OXALIPLATIN , CISPLATIN

    Merck Sharp and Dohme

    Gastric and gastric esophageal junction (GEJ) adenocarcinoma

    phase 3 small molecule active

    1 trial

  11. Placebo intramuscular injection

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Chronic Spontaneous Uriticaria

    phase 3 small molecule active

    1 trial

  12. Placebo is 0.9% (w/v) NaCl for injection and is to be provided by sites., IVX-A12

    AstraZeneca AB

    Respiratory Syncytial Virus and Human Metapneumovirus

    phase 3 small molecule active

    1 trial

  13. Placebo matching to garetosmab, Garetosmab

    Lacuna Pharma Pty Ltd

    Fibrodysplasia Ossificans Progressiva

    phase 3 small molecule active

    1 trial

  14. Placebo matching to spesolimab

    Boehringer Ingelheim

    Pyoderma gangrenosum

    phase 3 small molecule active

    1 trial

  15. Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg

    Amneal Pharma Europe Ltd

    Uncomplicated Urinary Tract Infections

    phase 3 small molecule completed

    1 trial

  16. Placebo of ZIMINO (glucose 5%), ZIMINO 2,5 mg/ml, solution à diluer pour perfusion

    Pari Pharma GmbH

    Patients referred for an isolated or a combined surgical correction of functional moderate to severe tricuspid regurgitation

    phase 3 small molecule active

    1 trial

  17. Placebo pMDI to match budesonide/formoterol fumarate pMDI, PREDNISOLONE, Placebo MDI to match to Budesonide, Glycopyronium and Formoterol Fumarate/ Budesonide and Formoterol Fumarate MDI, SALBUTAMOL, Trixeo Aerosphere 5 micrograms/7.2 micrograms/160 micrograms pressurised inhalation, suspension, Budesonide, Glycopyronium and Formoterol Fumarate, Symbicort, 160 mikrogram/4,5 mikrogram/puff inhalationsspray, suspension

    AstraZeneca AB

    Severe and inadequately controlled asthma

    phase 3 small molecule active

    1 trial

  18. Placebo tablets to match S95032 drug product are supplied as film-coated tablets for oral administration., S95032/AG-881, S95032/AG-881

    Ningbo Cancer Hospital

    ​​IDH-mutant grade 2 or 3 astrocytoma​

    phase 3 small molecule active

    1 trial

  19. Placebo to AIN457 150 mg/ 1 mL Solution for injection in pre-filled syringe. This placebo is an additional/ alternative placebo to placebo to Xolair® (Omalizumab) to ensure continuous supply in the clinical trial. For more details please refer to Note to Assessor located in the “Placebo to AIN457” product shell., OMALIZUMAB , -, Placebo to Xolair® (Omalizumab) 150 mg/ml solution for injection in pre-filled syringe, LOU064, Placebo to Remibrutinib (LOU064) 25 mg film-coated tablet, -

    Novartis Pharmaceuticals

    Chronic Spontaneous Urticaria

    phase 3 small molecule active

    1 trial

  20. Placebo to Basimglurant (Microcrystalline Cellulose Spheres (Vivapur 1000) and hard Gelatin Capsule, Opaque white body/Opaque white cap, Size 1), Basimglurant, Basimglurant

    Lacuna Pharma Pty Ltd

    Trigeminal neuralgia, Trigeminal neuralgia

    phase 3 small molecule active

    1 trial

  21. Placebo to Imetelstat, -, -, IMETELSTAT

    Geron Netherlands B.V.

    Myelodysplastic syndromes (MDS)

    phase 3 small molecule active

    1 trial

  22. Placebo to Keytruda - Normal Saline Solution, GEMCITABINE, CISPLATIN, KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Cis-eligible Muscle-invasive bladder cancer.

    phase 3 small molecule active

    1 trial

  23. Placebo to Mexiletine granules for prolonged-release oral suspension 167 mg, 333 mg, and 500 mg, Mexiletine granules for prolonged-release oral suspension 333 mg, Mexiletine granules for prolonged-release oral suspension 500 mg, Mexiletine granules for prolonged-release oral suspension 167 mg

    Lupin Europe GmbH

    Myotonic Dystrophy type 1 and type 2 (DM1/DM2)

    phase 3 small molecule active

    1 trial

  24. Placebo to Pembrolizumab, CISPLATIN , KEYTRUDA 25 mg/mL concentrate for solution for infusion

    Merck Sharp and Dohme

    Locally Advanced Cervical Cancer

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources